VCAM-1-antagonising peptides and antibodies have been widely utilised as targeting moieties for visualising inflammation and delivering anti-inflammatory agents in disease pathologies involving endothelial dysfunction, particularly atherosclerosis [109, 110]. Here, VCAM1 is linked to atherosclerosis.